

Abiraterone STAMPEDE

PRELIMINARY SCORE


CURATIVE

NON-CURATIVE


OS

ADJUSTMENTS


Quality of life




QoL data pending




Serious and disabling adverse effects






Other adjustments



Early stopping or crossover



Abiraterone STAMPEDE

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: Newly diagnosed high risk mHSPC in patients adult men  
Experimental Arm: Abiraterone + Prednisone + ADT (androgen deprivation therapy)  
Control Arm: ADT + placebo

